美国退伍军人中呼吸道合胞病毒疫苗有效性的持久性
该目标试验模拟使用退伍军人健康管理局数据,纳入2023年9月至2024年3月符合RSV疫苗接种条件的≥60岁退伍军人,比较单剂重组稳定预融合F蛋白RSV疫苗与未接种。疫苗组288 111人与对照组1 075 893人匹配后加权代表576 222人,中位随访15.8个月。对确诊RSV感染的疫苗有效性从0-1个月的82.5%(95%CI 77.5%-86.9%)降至0-18个月的59.4%(95%CI 55.6%-63.5%);对急诊/紧急护理就诊从84.9%降至60.5%,对住院从88.9%降至57.3%,对ICU入住从92.5%降至71.9%。免疫功能低下者保护下降更显著(75.2%→39.7%)。结论认为RSV疫苗有效但两个季节内保护下降,作者建议审查特定风险人群增加剂次是否获益。
要点
- ≥60岁退伍军人单剂重组预融合F蛋白RSV疫苗对确诊RSV感染的 effectiveness 0-1个月为82.5%(95%CI 77.5%-86.9%),0-18个月降至59.4%(95%CI 55.6%-63.5%)。
- 对RSV相关住院的 effectiveness 从0-1个月88.9%(95%CI 77.9%-95.7%)降至0-18个月57.3%(95%CI 47.3%-66.4%)。
- 对RSV相关ICU入住的 effectiveness 0-1个月为92.5%(95%CI 61.1%-100.0%),0-18个月为71.9%(95%CI 42.8%-90.0%)。
- 免疫功能低下者中对确诊感染的 protection 从0-1个月75.2%(95%CI 52.5%-89.3%)降至0-18个月39.7%(95%CI 23.9%-52.7%)。
- 作者认为需审查特定风险人群增加疫苗剂次是否可能获益。
适用人群与场景
- 2023年9月至2024年3月符合RSV疫苗接种条件的≥60岁退伍军人,数据来自退伍军人健康管理局。
- 匹配后加权人群共576 222人,其中544 364人(94.5%)为男性,中位年龄76.1岁(IQR 71.6-80.0)。
研究设计与关键结果
- 研究设计为目标试验模拟,纳入288 111名接种者与1 075 893名未接种者匹配(1:最多4),加权代表576 222人,中位随访15.8个月(IQR 14.5-17.0)。
- 主要终点任何RSV检测阳性:疫苗有效性从0-1个月82.5%(95%CI 77.5%-86.9%)降至0-18个月59.4%(95%CI 55.6%-63.5%)。
- 次要终点RSV相关急诊或紧急护理就诊:有效性从0-1个月84.9%(95%CI 78.4%-90.2%)降至0-18个月60.5%(95%CI 56.4%-65.7%)。
- 次要终点RSV相关住院:有效性从0-1个月88.9%(95%CI 77.9%-95.7%)降至0-18个月57.3%(95%CI 47.3%-66.4%)。
- 次要终点RSV相关ICU入住:有效性0-1个月92.5%(95%CI 61.1%-100.0%),0-18个月71.9%(95%CI 42.8%-90.0%)。
- 免疫功能低下者中对确诊感染的 protection 从0-1个月75.2%(95%CI 52.5%-89.3%)降至0-18个月39.7%(95%CI 23.9%-52.7%)。
证据类型、等级与局限
- 证据类型为目标试验模拟(target trial emulation),使用退伍军人健康管理局数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为RSV疫苗可有效预防RSV疾病及相关医疗使用,但保护在两个季节内下降。
- 作者认为免疫功能低下者保护下降最显著,提示需审查特定风险人群增加疫苗剂次是否可能获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A single respiratory syncytial virus (RSV) vaccine dose is recommended for older adults and persons at increased risk for severe RSV. Clinical information on the long-term effectiveness of RSV vaccines is needed.
OBJECTIVE: To determine the effectiveness of RSV vaccination over 2 respiratory illness seasons.
DESIGN, SETTING, AND PARTICIPANTS: This target trial emulation used data from the Veterans Health Administration and included veterans 60 years and older who were eligible for RSV vaccination from September 2023 to March 2024.
EXPOSURE: A single dose of a recombinant stabilized prefusion F protein RSV vaccine vs no RSV vaccination.
MAIN OUTCOMES AND MEASURES: Eligible vaccine recipients were matched with up to 4 unvaccinated individuals in 7 monthly, nested sequential trials from September 1, 2023, to March 31, 2024. Outcomes were ascertained through March 31, 2025. The primary outcome was any positive RSV test result from day 14 following the matched index date. Secondary outcomes included RSV-associated emergency department or urgent care visits, hospitalizations, or intensive care unit admissions. Vaccine effectiveness was estimated as 100 × (1 - risk ratio).
RESULTS: A total of 288 111 vaccinated individuals were matched to 1 075 893 unique control individuals, weighted equally to represent 576 222 individuals, and followed up for a median of 15.8 months (IQR, 14.5-17.0). Across both groups, 544 364 of 576 222 veterans (94.5%) were male, and the median age was 76.1 years (IQR, 71.6-80.0). Vaccine effectiveness against documented RSV infections decreased from 82.5% (95% CI, 77.5%-86.9%) over 0 to 1 month to 59.4% (95% CI, 55.6%-63.5%) over 0 to 18 months of follow-up. During the same period, effectiveness decreased from 84.9% (95% CI, 78.4%-90.2%) to 60.5% (95% CI, 56.4%-65.7%) for emergency visits and 88.9% (95% CI, 77.9%-95.7%) to 57.3% (95% CI, 47.3%-66.4%) for hospitalizations and was 92.5% (95% CI, 61.1%-100.0%) and 71.9% (95% CI, 42.8%-90.0%) for intensive care unit admissions. Among immunocompromised individuals, protection against documented infections decreased from 75.2% (95% CI, 52.5%-89.3%) to 39.7% (95% CI, 23.9%-52.7%).
CONCLUSIONS AND RELEVANCE: The study found that RSV vaccination was effective in preventing RSV illness and associated health care use but that protection decreased over 2 seasons. Reductions were most notable among immunocompromised persons, suggesting the need to review whether additional vaccine doses may benefit certain risk groups.
参考来源
- Bajema KL, Bui DP, Yan L, et al. Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans. JAMA Intern Med. 2026. PMID: 41284307. doi:10.1001/jamainternmed.2025.6355
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。